Literature DB >> 3062767

The use of immunoblotting to detect antibodies to nuclear and cytoplasmic antigens. Clinical and serological associations in rheumatic diseases.

D J de Rooij1, L B van de Putte, W J Habets, A L Verbeek, W J van Venrooij.   

Abstract

Using the immunoblotting technique, sera from 433 patients with rheumatic diseases were screened for the presence of antibodies against several nuclear and cytoplasmic antigens, such as RNP, Sm, Ro(SSA), La(SSB), CR-19 (centromeric antigen), Topo-1 (Scl-70), Jo-1, histone and 56 kD. At the same time clinical data from these patients were collected without prior knowledge of the immunoblotting results. Syndrome-specific autoantibodies were found for mixed connective tissue disease (antibodies against the RNP related 70 kD antigen), for CREST (anti-CR-19 antibodies), for diffuse scleroderma (anti-Topo-1 antibodies) and for polymyositis (anti-Jo-1 antibodies). Almost all specific autoantibodies were present exclusively in patients with a connective tissue disease. Controls were only in a few cases positive for antihistone and anti-56 kD antibodies. Associations of specific autoantibodies with clinical and laboratory features of the patients were mostly as expected. However, some unexpected associations were found, for example polymyositis and calcinosis with anti-Sm antibodies, sicca symptoms with anti-centromere antibodies and leucopenia with Ro(SSA) and La(SSB).

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3062767     DOI: 10.3109/03009748809105271

Source DB:  PubMed          Journal:  Scand J Rheumatol        ISSN: 0300-9742            Impact factor:   3.641


  19 in total

Review 1.  Coexistence of antitopoisomerase I and anticentromere antibodies in patients with systemic sclerosis.

Authors:  T Dick; R Mierau; P Bartz-Bazzanella; M Alavi; M Stoyanova-Scholz; J Kindler; E Genth
Journal:  Ann Rheum Dis       Date:  2002-02       Impact factor: 19.103

Review 2.  Antinuclear antibody determination methods.

Authors:  D G Williams; P J Charles; M Field; S M Chua; R N Maini
Journal:  Clin Rheumatol       Date:  1990-03       Impact factor: 2.980

3.  Inhibiting effect of charged polymers on interaction of human lupus autoantibodies with certain intracellular proteins.

Authors:  A E Kabakov; L N Brovkina; A M Poverenny; L Cebecauer
Journal:  Rheumatol Int       Date:  1992       Impact factor: 2.631

4.  Use of recombinant RNP peptides 70K and A in an ELISA for measurement of antibodies in mixed connective tissue disease: a longitudinal follow up of 18 patients.

Authors:  D J de Rooij; W J Habets; L B van de Putte; M H Hoet; A L Verbeek; W J van Venrooij
Journal:  Ann Rheum Dis       Date:  1990-06       Impact factor: 19.103

Review 5.  Anti-Ro(SSA) and anti-La(SSB) antibodies in autoimmune rheumatic diseases.

Authors:  P Youinou; Y Adler; S Muller; A Lamour; D Baron; R L Humbel
Journal:  Clin Rev Allergy       Date:  1994

6.  Occurence of autoantibodies in healthy Omani individuals.

Authors:  Ali A Al-Jabri; Elizabeth R Richens
Journal:  J Sci Res Med Sci       Date:  2001-04

7.  A recombinant topoisomerase I used for autoantibody detection in sera from patients with systemic sclerosis.

Authors:  R Verheijen; F Van den Hoogen; R Beijer; A Richter; E Penner; W J Habets; W J van Venrooij
Journal:  Clin Exp Immunol       Date:  1990-04       Impact factor: 4.330

8.  Antiperinuclear factor, a marker autoantibody for rheumatoid arthritis: colocalisation of the perinuclear factor and profilaggrin.

Authors:  R M Hoet; A M Boerbooms; M Arends; D J Ruiter; W J van Venrooij
Journal:  Ann Rheum Dis       Date:  1991-09       Impact factor: 19.103

9.  Epitope regions on U1 small nuclear RNA recognized by anti-U1RNA-specific autoantibodies.

Authors:  R M Hoet; P De Weerd; J K Gunnewiek; I Koornneef; W J Van Venrooij
Journal:  J Clin Invest       Date:  1992-11       Impact factor: 14.808

10.  A recombinant topoisomerase I ELISA: screening for IgG, IgM and IgA anti-topo I autoantibodies in human sera.

Authors:  R Verheijen; B A de Jong; W J van Venrooij
Journal:  Clin Exp Immunol       Date:  1992-09       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.